BTIG analyst Ryan Zimmerman lowered Intuitive Surgical’s price target to $574 from $616 on April 13, while keeping a Buy rating [1].
The adjustment matters because analysts’ targets influence institutional buying and can sway the stock’s momentum, especially for a company whose da Vinci surgical systems dominate the robotic‑assisted surgery market.
Zimmerman said the Centers for Medicare & Medicaid Services’ FY27 payment rule could lower hospital reimbursement for robotic procedures – a shift that may slow adoption of Intuitive’s technology in Medicare‑funded facilities [1]. The rule, which revises how Medicare values certain high‑cost devices, is expected to take effect in the 2027 fiscal year.
Investors will watch Intuitive’s quarterly earnings for signs that the reimbursement change is already affecting procedure volumes. A lower target suggests analysts anticipate slower revenue growth, even as the company expands its product line, and pursues international markets.
Despite the cut, BTIG maintains a Buy rating on Intuitive Surgical, indicating confidence that the company’s long‑term earnings potential remains strong. "BTIG maintains a Buy rating on Intuitive Surgical despite the target cut," the note said.
Intuitive Surgical, founded in 1995, pioneered the da Vinci platform, which now accounts for a significant share of the $7 billion global robotic surgery market. The firm’s revenue grew 13 percent last year, but analysts warn that tighter Medicare payments could compress margins.
The price‑target reduction reflects a broader analyst trend of reassessing medical‑device valuations as payer policies evolve. As hospitals balance cost pressures with the clinical benefits of robotics, companies may need to demonstrate clear value to retain procedure volume.
**What this means** The new target signals that the CMS FY27 payment rule is a material risk factor for Intuitive Surgical’s growth outlook. While the Buy rating suggests confidence in the company’s fundamentals, investors should monitor reimbursement trends and hospital adoption rates, which could shape the stock’s performance over the next several years.
“Zimmerman lowered the price target to $574, down from $616.”
The revised target underscores that changes in Medicare reimbursement policy are now a key variable in forecasting Intuitive Surgical’s revenue trajectory, prompting investors to weigh policy risk alongside the company’s technological leadership.
